mepsevii
ultragenyx germany gmbh - vestronidase alfa - mucopolysaccharidosis vii - encimi - mepsevii je primerna za zdravljenje ne-nevrološke manifestacije mucopolysaccharidosis vii (mps vii; sly sindrom).
talzenna
pfizer europe ma eeig - talazoparib - neoplazme dojke - antineoplastična sredstva - talzenna je označen kot monotherapy za zdravljenje odraslih bolnikov z germline brca1/2 mutacije, ki so her2-negativne lokalno napredno ali metastatskega raka dojke. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. bolniki z hormon receptorjev (hr)-pozitivnega raka dojk, je bilo treba ravnati predhodno endokrine, ki temelji terapije, ali neprimerna za endokrine, ki temelji terapija.
nexviadyme
sanofi b.v. - avalglucosidase alfa - bolezen tipa ii za shranjevanje glikogena - drugi zdravljene bolezni prebavil in presnove izdelki, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).
vyvgart
argenx - efgartigimod alfa - myasthenia gravis - imunosupresivi - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.
enjaymo
sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imunosupresivi - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).